- Home
- CLSK vs CDNA Comparison
CLSK vs CDNA Comparison
Compare CLSK & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLSK | CDNA |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2008 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CLSK | CDNA |
|---|---|---|
| Price | $12.64 | $53.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $19.44 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 17.4M | 1.1M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | ★ $766,314,000.00 | $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | $19.87 | $11.31 |
| P/E Ratio | ★ N/A | $23.60 |
| Revenue Growth | ★ 102.21 | 18.93 |
| 52 Week Low | $8.00 | $13.72 |
| 52 Week High | $23.61 | $53.67 |
Technical Indicators
Market Signals| Indicator | CLSK | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 67.26 |
| Support Level | $12.02 | $45.74 |
| Resistance Level | $13.76 | $53.67 |
| Average True Range (ATR) | 0.85 | 2.49 |
| MACD | 0.23 | -0.33 |
| Stochastic Oscillator | 78.22 | 81.37 |
Price Performance
Historical ComparisonAbout CLSK CleanSpark Inc.
Cleanspark Inc. is a data center developer that, until recently, focused exclusively on bitcoin mining. The company provides scalable, energy-efficient digital infrastructure across the United States. The Company has a sole reporting segment, which is the bitcoin mining segment.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.